We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Study Provides More Clues into Role of Vitamin D in Cancer Prevention

By Biotechdaily staff writers
Posted on 04 Sep 2007
A new study looking at the relationship between vitamin D serum levels and the risk of colon and breast cancer worldwide has estimated the number of cases of cancer that could be prevented each year if vitamin D3 levels met the objective proposed by researchers.

Cedric F. More...
Garland, Dr.P.H., cancer prevention specialist at the Moores Cancer Center at the University of California, San Diego (UCSD; USA) and colleagues estimate that 250,000 cases of colorectal cancer and 350,000 cases of breast cancer could be prevented worldwide by increasing intake of vitamin D3, particularly in countries north of the equator. Vitamin D3 is available through diet, supplements, and exposure of the skin to sunlight.

"For the first time, we are saying that 600,000 cases of breast and colorectal cancer could be prevented each year worldwide, including nearly 150,000 in the United States alone,” said study co-author Garland. The study, which examines the dose-response relationship between vitamin D and cancer, was published in the August 2007 issue of the journal Nutrition Reviews.

The study combined data from surveys of serum vitamin D levels during winter from 15 countries. It is the first such study to evaluate satellite measurements of sunshine and cloud cover in countries where actual blood serum levels of vitamin D3 had also been determined. The data were then applied to 177 countries to estimate the average serum level of a vitamin D metabolite of people living there.

The study's findings revealed an inverse association of serum vitamin D with risk of colorectal and breast cancer. The protective effect began at levels ranging from 24 to 32 ng per ml of 25-hydroxyvitamin D concentration in the serum. The 25-hydroxyvitamin D level is the primary indicator of vitamin D status. The late winter average 25-hydroxyvitamin D in the United States is approximately 15-18 ng/ml. The researchers maintain that increasing vitamin D levels in populations, especially those in northern climates, has the potential to both prevent and possibly serve as an adjunct to existing treatments for cancer.

The study supports previous studies by Dr. Garland and colleagues (Journal of Steroid Biochemistry and Molecular Biology, February 2007), which found that raising the serum 25(OH)D levels to 55 ng/ml was optimal for cancer prevention. This is the first study, however, to recommend optimal vitamin D serum levels, which, according to Dr. Garland, are high enough to provide the needed benefit but which have been found by other scientists to be low enough to avoid health risks.

"This could be best achieved with a combination of diet, supplements, and short intervals--10 or 15 minutes a day--in the sun,” said Dr. Garland. It could be less for very fair-skinned individuals. He went on to report, "the appropriate dose of vitamin D in order to reach this level, could be very little in a lifeguard in Southern California...or quite a lot for someone in Northern Europe who tends to remain indoors most of the year.”

The serum level recommended by the study would correspond to intake of 2,000 International Units (IU) per day of vitamin D3 for a meaningful reduction in colorectal cancer. The researchers recommend 2000 IU/day, plus, when weather allows, a few minutes in the sun with at least 40% of the skin exposed, for a meaningful decrease in breast cancer incidence, unless the individual has a history of skin cancer or a photosensitivity disease. Dr. Garland also recommends moderate sun exposure and use of clothing and a hat when in the sun longer than 15 minutes.

This study used worldwide data only recently available through a new tool called GLOBOCAN, developed by the World Health Organization's International Agency for Research on Cancer. GLOBOCAN is a database of cancer incidence, mortality, and prevalence for 177 countries. Earlier research from this core group have shown an association between higher levels of vitamin D3 or markers of vitamin D status and lower risk of cancers of the breast, colon, ovary, and kidney.

The researchers emphasized their call for prompt public health action to increase intake of vitamin D3 as an inexpensive tool for prevention of diseases that claim nearly one million lives each year worldwide. "The message is, depending on where you live, you may need to consider taking in considerably higher levels of vitamin D3 than those currently recommended,” said Dr. Garland. "I'd recommend discussing vitamin D needs with a healthcare professional, who may order and interpret a simple blood test for a vitamin D metabolite [25(OH)D], and provide a dosage recommendation that's appropriate for the individual's needs.”


Related Links:
University of California, San Diego

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.